Agios Pharma rises after US FDA expands use of co's drug for blood disorder

Shares of drugmaker Agios Pharmaceuticals AGIO.O rise 8.6% to $26.70 premarket

Company said late on Tuesday that the U.S. Food and Drug Administration has approved the expanded use of its drug for treatment of a type of blood disorder

The drug, mitapivat, under brand name of Aqvesme, was being tested for the treatment of anemia in adults with alpha- or beta-thalassemia

The inherited condition affects the body's ability to produce hemoglobin and healthy red blood cells

Mitapivat was approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd

As of last close, stock down 25.2% YTD